The GOLD Guidelines for the Diagnosis and Treatment of Patients With COPD

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006). http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989 (accessed August 2007).
Anonymous. Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007.
Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 502–6.
Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004; 98: 932–7.
Rabe KF, Hurd S, Anzueto A et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–55.
American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Version 1.2, 2004. http://www.thoracic.org/go/copd (accessed September 2007).
O'Donnell DE, Aaron S, Bourbeau J et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease. Can Resp J 2003; 10 (Suppl. A): 11A–65A.
Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl. 1): 1–232.
Tsagaraki V, Markantonis SL, Amfilochiou A. Pharmacotherapeutic management of COPD patients in Greece – adherence to international guidelines. J Clin Pharm Ther 2006; 31: 369–74.
Buist AS. Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes. Eur Respir J Suppl 2003; 39: 30s–5s.
Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125: 1394–9.
Miravitlles M, Mayordomo C, Artes M et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med 1999; 93: 173–9.
Heffner JE. Using COPD guidelines to improve patient care. Am Fam Physician 2006; 73: 590–1.
Mularski RA, Asch SM, Shrank WH et al. The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest 2006; 130: 1844–50.
Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672–88.
Pinto-Plata V, Toso J, Lee K et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007; 62: 595–601.
Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341–57.
Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med 2005; 26: 154–66.
Stoller JK. Alpha-1 antitrypsin deficiency: an under-recognized but important issue for respiratory therapists. Respir Care 2003; 48: 1022–4.
Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006; 129: 1068–87.
Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 176–83.
Fabbri LM, Romagnoli M, Corbetta L et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 418–24.
Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004; 1: 264–8.
Guerra S. Overlap of asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2005; 11: 7–13.
Elias JA. Airway remodeling in asthma. Unanswered questions. Am J Respir Crit Care Med 2000; 161: S168–71.
Dewar M, Curry RW Jr. Chronic obstructive pulmonary disease: diagnostic considerations. Am Fam Physician 2006; 73: 669–76.
Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc 2006; 3: 176–9.
Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006; 119: 21–31.
Tinkelman D, Corsello P. Chronic obstructive pulmonary disease: the impact occurs earlier than we think. Am J Manag Care 2003; 9: 767–71.
Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006; 43: 75–80.
Tiep BL, Carter R. COPD Disease Management. http://www.thoracic.org/sections/clinical-information/best-of-the-web/pages/obstructive-disease/copd-disease-management.html (accessed December 2007).
Hughes SL, Weaver FM, Giobbie-Hurder A et al. Effectiveness of team-managed home-based primary care: a randomized multicenter trial. JAMA 2000; 284: 2877–85.
Bourbeau J, Collet JP, Schwartzman K et al. Economic benefits of self-management education in COPD. Chest 2006; 130: 1704–11.
Currie GP, Rossiter C, Miles SA et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19: 112–9.
Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002; 110: S298–303.
Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330: 640–4.
Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005; 11: 121–8.
Briggs DD Jr, Doherty DE. Long-term pharmacologic management of patients with chronic obstructive pulmonary disease. Clin Cornerstone 2004; Suppl 2: S17–28.
van Noord JA, Smeets JJ, Custers FL et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639–44.
Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005; 27: 377–92.
Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24.
Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209–16.
van Noord JA, Bantje TA, Eland ME et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289–94.
Lotvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med 2000; 94 (Suppl. E): S6–10.
Rodriguez-Carballeira M, Heredia JL, Rue M et al. The bronchodilator test with increasing doses of terbutaline in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther 2001; 14: 61–5.
Pino-Garcia JM, Garcia-Rio F, Gomez L et al. Short-term effects of inhaled beta-adrenergic agonist on breathlessness and central inspiratory drive in patients with nonreversible COPD. Chest 1996; 110: 637–41.
Benhamou D, Cuvelier A, Muir JF et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001; 95: 817–21.
Bensch G, Lapidus RJ, Levine BE et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19–27.
Kottakis J, Cioppa GD, Creemers J et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002; 9: 107–15.
Condemi JJ. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin Ther 2001; 23: 1529–41.
Lipson DA. Redefining treatment in COPD: new directions in bronchodilator therapy. Treat Respir Med 2004; 3: 89–95.
Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058–69.
Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.
Hanania NA, Kalberg C, Yates J et al. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005; 18: 19–22.
Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–65.
Foradil^® Aerolizer^® (formoterol fumarate inhalation powder). Full Prescribing Information, Kenilworth, NJ: Schering Corporation, 2006.
Serevent^® Diskus^® (salmeterol xinafoate inhalation powder). Full Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline, 2006.
Nelson HS, Weiss ST, Bleecker ER et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26.
Mann M, Chowdhury B, Sullivan E et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124: 70–4.
Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167: 813–8.
ZuWallack RL, Mahler DA, Reilly D et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661–70.
Cazzola M, Centanni S, Santus P et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98: 1214–21.
Cazzola M, Di Perna F, Califano C et al. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Pulm Pharmacol Ther 1999; 12: 267–71.
van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411–9.
Tashkin D, Varghese S. Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD (Abstract). J Allergy Clin Immunol 2007; 119: S4.
Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042–50.
Rabe KF, Timmer W, Sagriotis A, Viel K. [Abstract] Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Eur Respir J 2005; 26: 14s.
Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–303.
Vestbo J, Sorensen T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–23.
Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948–53.
Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
Celli B, Ferguson G, Anderson J et al. Salmeterol/Fluticasone Propionate (SFC) Improves Lung Function and Reduces the Rate of Decline Over Three Years in the TORCH Survival Study. (Abstract). Am J Respir Crit Care Med 2007; 175: A763.
Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834–43.
Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81.
Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–9.
Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–9.
Wongsurakiat P, Maranetra KN, Wasi C et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125: 2011–20.
Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007; 22: 62–7.
Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189–95.
Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995; 152: 861–4.
Clark NM, Nothwehr F, Gong M et al. Physician–patient partnership in managing chronic illness. Acad Med 1995; 70: 957–9.
Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–8.
Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, June 2000.
Celli BR. Pulmonary rehabilitation for COPD. A practical approach for improving ventilatory conditioning. Postgrad Med 1998; 103: 159– 60, 67– 8, 73–6.
Cooper CB. Exercise in chronic pulmonary disease: aerobic exercise prescription. Med Sci Sports Exerc 2001; 33: S671–9.
Storer TW. Exercise in chronic pulmonary disease: resistance exercise prescription. Med Sci Sports Exerc 2001; 33: S680–92.
Green RH, Singh SJ, Williams J, Morgan MD. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001; 56: 143–5.
Casaburi R, Porszasz J, Burns MR et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 1541–51.
Porszasz J, Emtner M, Goto S et al. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128: 2025–34.
Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–17.
Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 2003; 123: 1460–6.
Sahebjami H, Sathianpitayakul E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 886–90.
California Pulmonary Rehabilitation Collaborative Group. Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California. J Cardiopulm Rehabil 2004; 24: 52–62.
Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003; 167: 880–8.
Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333: 710–4.
Petty TL, Bliss PL. Ambulatory oxygen therapy, exercise, and survival with advanced chronic obstructive pulmonary disease (the Nocturnal Oxygen Therapy Trial revisited). Respir Care 2000; 45: 204–11; discussion 11–3.
Budweiser S, Hitzl AP, Jorres RA et al. Impact of noninvasive home ventilation on long-term survival in chronic hypercapnic COPD: a prospective observational study. Int J Clin Pract 2007; 61: 1516–22.
Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J 2007; 30: 293–306.
Kramer N, Meyer TJ, Meharg J et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799–806.
Brochard L, Isabey D, Piquet J et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990; 323: 1523–30.
Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931–5.
Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995; 5: 717–34.
Martinez FJ, de Oca MM, Whyte RI et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155: 1984–90.
National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345: 1075–83.
Patel N, Criner GJ. Transplantation in chronic obstructive pulmonary disease. COPD 2006; 3: 149–62.
Stavem K, Bjortuft O, Borgan O et al. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. J Heart Lung Transplant 2006; 25: 75–84.
Wang Q, Bourbeau J. Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD. Respirology 2005; 10: 334–40.
Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31.
Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006; 61: 250–8.
Hernandez C, Casas A, Escarrabill J et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21: 58–67.
Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
Aaron SD, Vandemheen KL, Hebert P et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618–25.
Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003; 327: 643.
Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–60.
Ram FS, Rodriguez-Roisin R, Granados-Navarette A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev 2007; 3: 1–39.

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Leonard Fromer, MD, FAAFP

Department of Family Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California

Disclosures

Disclosure: Leonard Fromer, MD, FAAFP, has disclosed that he has received an honorarium for his annual participation on one of Schering-Plough's advisory boards.

Christopher B. Cooper, MD

Departments of Medicine and Physiology, David Geffen School of Medicine, UCLA, Los Angeles, California

Disclosures

Disclosure: Christopher B. Cooper, MD, has disclosed that he has served as a consultant for and on the advisory board of BIPI, Pfizer, VIASYS, Emphasys Medical, and ROX Medical. Dr. Cooper has also disclosed that he has served on the speaker's bureau for and has received honoraria from BIPI, GlaxoSmithKline, Pfizer, Dey, and AstraZeneca, and has received grant support from BIPI, GlaxoSmithKline, Fenzian (Fenzian is a transcutaneous stimulator device that is being studied in patients with mild asthma), and Spiration.

processing....

Sidebar: Review Criteria

Key information from the GOLD guidelines (2006) was selected for this review, often chosen from headings and subheadings designated within the guidelines. Additional supporting information was obtained from primary or review manuscripts found during a PubMed subject search for relevant material.

Message for the Clinic

National COPD guidelines compiled by an expert panel provide up-to-date information for the practicing physician to understand and treat COPD. Compliance with these guidelines may improve clinical outcomes for COPD patients.

Acknowledgements

Editorial assistance was provided by Erin Scott, PhD.

Funding Information

This assistance was funded by Schering-Plough.

Reprint Address

Leonard Fromer, Department of Family Medicine, David Geffen School of Medicine, UCLA, 15525 Hamner Drive, Los Angeles, CA 90077, USA; Tel.: + 1 310 383 8168; Fax: + 1 310 471 5392; Email:[email protected]

CLICK HERE for subscription information about this journal.